A phase 3 clinical trial (ESSENCE, NCT04822181) is recruiting non-cirrhotic NASH patients to evaluate the potential resolution of steatohepatitis and the improvement in fibrosis with this GLP-1R agonist. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.